Adaptive Phage Therapeutics: Funding, Investors & Team (Sep 2026)
Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. Its services are provided using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistant bacteria.
Adaptive Phage Therapeutics has raised $77.8M across 4 funding rounds on record, the most recent a Series B of $12.0M announced in Jun 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Adaptive Phage Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2023.
Adaptive Phage Therapeutics Funding Rounds
Adaptive Phage Therapeutics raised $40.8M in an undisclosed round announced in May 2021.
11 months later, a Series B of $20.0M was announced in Apr 2022.
6 months later, a Grant of $5.0M was announced in Oct 2022.
8 months later, a Series B of $12.0M was announced in Jun 2023.
Adaptive Phage Therapeutics Founders and Leadership Team
Contact details for the Adaptive Phage Therapeutics team: 3 of 4 have an email address on file.
Start 14-day free trial →Adaptive Phage Therapeutics Funding Compared to Other Biotechnology Startups
Adaptive Phage Therapeutics' latest round of $12.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Adaptive Phage Therapeutics in Biotechnology and Bethesda
Companies Similar to Adaptive Phage Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Adaptive Phage Therapeutics Funding FAQs
What does Adaptive Phage Therapeutics do?
Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. Its services are provided using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistant bacteria.
How much funding has Adaptive Phage Therapeutics raised?
Adaptive Phage Therapeutics has raised $77.8M across 4 rounds on record. The most recent is a Series B of $12.0M announced in Jun 2023.
When did Adaptive Phage Therapeutics last raise funding?
Adaptive Phage Therapeutics' most recent funding round on record is a Series B of $12.0M, announced in Jun 2023.
Who founded Adaptive Phage Therapeutics?
FundedIQ lists Carl Merril (Founder), Gregory L Merril (Founder) at Adaptive Phage Therapeutics.
Who is the CEO of Adaptive Phage Therapeutics?
Greg Merril is listed as CEO at Adaptive Phage Therapeutics.
Where is Adaptive Phage Therapeutics headquartered?
Adaptive Phage Therapeutics is based in Bethesda, Maryland, United States.
How many employees does Adaptive Phage Therapeutics have?
Adaptive Phage Therapeutics is in the 51-100 employee band.
How does Adaptive Phage Therapeutics' funding compare to other Biotechnology startups?
Adaptive Phage Therapeutics' latest round of $12.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Adaptive Phage Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Adaptive Phage Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.